Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12614001057673
Ethics application status
Approved
Date submitted
4/04/2014
Date registered
3/10/2014
Date last updated
6/08/2019
Date data sharing statement initially provided
6/08/2019
Date results information initially provided
6/08/2019
Type of registration
Retrospectively registered
Titles & IDs
Public title
QUADPILL Pilot Feasibility Study: Can an ultra low-dose 'hypertension polypill' provide better blood pressure control with fewer side effects?
Query!
Scientific title
Can an ultra low-dose 'hypertension polypill' provide better blood pressure control with fewer side effects? Feasibility study.
Query!
Secondary ID [1]
283924
0
nil
Query!
Universal Trial Number (UTN)
U1111-1152-2426
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypertension
290927
0
Query!
Condition category
Condition code
Cardiovascular
291282
291282
0
0
Query!
Hypertension
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The Quadpill will be a single gelatin capsule containing 1/4 standard doses of 4 common blood pressure lowering medications (Irbesartan 37.5 mg, Amlodipine 1.25 mg, Atenolol 12.5 mg and Hydrochlorothiazide 6.25 mg). Participants are randomly allocated to intervention or control therapy during the first cross-over period. Participants allocated to intervention will take one Quadpill orally once daily for 4 weeks, followed by a 2 week wash-out period and then a 4 week period where they will receive an identical looking tablet that contains placebo. Participants allocated to control first will receive the above in reverse.
There are no additional strategies to improve adherence to the intervention. Adherence will be monitored by drug tablet return and self-report.
Query!
Intervention code [1]
288613
0
Treatment: Drugs
Query!
Comparator / control treatment
The trial drug will be evaluated against Placebo. However due to the cross over design all participants will receive intervention (Quadpill) and Control (Placebo) at different time-points during the study. Placebo will appear identical to the intervention and be a single gelatin capsule containing sugar pills instead of active ingredients.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
291281
0
Systolic blood pressure: Patients will be rested in the seated position for 5 minutes, an appropriate cuff size will be selected, the cuff wrapped around the upper arm and the bladder centred over the brachial artery and 3 measurements of blood pressure will be recorded using an Omron automated digital blood pressure monitor. The monitor will be validated every 6 months and serviced at least once every 12 months according to the Heart Foundation recommendations
Query!
Assessment method [1]
291281
0
Query!
Timepoint [1]
291281
0
After 4 weeks of active treatment
Query!
Secondary outcome [1]
306417
0
Percentage achieving blood pressure control <140/90 using an Omron automated digital blood pressure monitor
Query!
Assessment method [1]
306417
0
Query!
Timepoint [1]
306417
0
Assessed at 4 weeks and at 10 weeks due to crossover design. Percentage achieving control after 4 weeks of active treatment.
Query!
Secondary outcome [2]
310377
0
Safety profile - through monitoring of blood and urine test (Electrolytes, Renal function, liver function, blood sugar); clinical follow-up using standardised questionnaires asking about side effects/ adverse effects. The questionnaire has been designed to evaluate side effects/ adverse effects that can be associated with the trial medications. For example participants will be asked if they have suffered any side effects, dizziness, blurred vision, syncope/ collapse, chest pain/ angina, shortness of breath, cough, wheeze, pedal edema (ankle swelling), skin rash, itching and other. If other they are asked to specify in a free text field. In addition blood and urine tests will be monitored as described above and any abnormalities recorded.
Query!
Assessment method [2]
310377
0
Query!
Timepoint [2]
310377
0
Safety is assess throughout both active and control treatments at 4 weeks and 10 weeks
Query!
Secondary outcome [3]
310378
0
Acceptability - will be assessed using standardised questionnaires. The questionnaire is not a named questionnaire but the questionnaire has been designed for this trial and uses questions from other polypill trials on acceptability.
Query!
Assessment method [3]
310378
0
Query!
Timepoint [3]
310378
0
At 10 weeks
Query!
Secondary outcome [4]
310379
0
Adhererence is assessed on pill counts and self-report e.g. have you missed any doses in the last 7 days.
Query!
Assessment method [4]
310379
0
Query!
Timepoint [4]
310379
0
Pill counts and self-reported medical adherence are assessed at 4 weeks and 10 weeks.
Query!
Secondary outcome [5]
310704
0
Mean 24 hour ambulatory blood pressure
Query!
Assessment method [5]
310704
0
Query!
Timepoint [5]
310704
0
Measured at 4 weeks and at 10 weeks.
Query!
Eligibility
Key inclusion criteria
1) Adults aged 18 years and over.
2) Systolic BP>140mmHg or diastolic BP> 90 mmHg on 2 readings on separate days.
3) Treatment Naive. (Not on medical treatment for hypertension).
4) No definite contraindications to quadpill medications, at the doses used in this trial.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1) The responsible clinician feels change in current therapy will place the patient at risk.
2) Severe or Accelerated Hypertension.
3) Pregnancy, Planning Pregnancy in 3 months, Lactating mothers
4) Inability to provide informed consent,
5) Medical illness with anticipated life expectancy < 3 months
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Potential participants will be identified from the community through advertising and through general practices. We will use advertising in community media (e.g. local newspapers), community radio or posters/ flyers. We will also identify potential participants by approaching general practices.
Randomisation will be 1:1 and conducted through a central, computer-based randomisation service. Treatment allocation will be blinded to both study staff and participants. Patients will be randomised to hypertension polypill i.e. 'Quadpill' or placebo in treatment period 1 and then to the opposite, ie control or Quadpill in the treatment period 2.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using computerised sequence generation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 3 / Phase 4
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
For a crossover trial a sample size of 50 patients at p is equal to 0.05 would have 90% power to detect a blood pressure difference of 12 mmHg between the intervention and control assuming an SD of 15mmHg and a SD of the within patient difference of 12 mmHg. This sample size takes into account the possibility of a 10% loss to follow-up.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/09/2014
Query!
Actual
1/09/2014
Query!
Date of last participant enrolment
Anticipated
1/06/2015
Query!
Actual
15/10/2015
Query!
Date of last data collection
Anticipated
Query!
Actual
29/12/2015
Query!
Sample size
Target
50
Query!
Accrual to date
Query!
Final
21
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Funding & Sponsors
Funding source category [1]
288564
0
Charities/Societies/Foundations
Query!
Name [1]
288564
0
Heart Foundation - Vanguard Grant 2013 App 100227
Query!
Address [1]
288564
0
Sydney Office Location:
Level 3, 80 William Street, East Sydney. NSW. 2011.
Query!
Country [1]
288564
0
Australia
Query!
Primary sponsor type
Charities/Societies/Foundations
Query!
Name
The George Institute for Global Health
Query!
Address
Level 10, King George V Building, Missenden Road, Camperdown. NSW. 2050
Query!
Country
Australia
Query!
Secondary sponsor category [1]
287278
0
University
Query!
Name [1]
287278
0
The University of Sydney
Query!
Address [1]
287278
0
The University of Sydney,
NSW. 2006.
Query!
Country [1]
287278
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
290427
0
The University of Sydney - Human Ethics Research Committee
Query!
Ethics committee address [1]
290427
0
Level 2, Margaret Telfer Building K07,
NSW. 2006.
Australia
Query!
Ethics committee country [1]
290427
0
Australia
Query!
Date submitted for ethics approval [1]
290427
0
13/01/2014
Query!
Approval date [1]
290427
0
08/04/2014
Query!
Ethics approval number [1]
290427
0
2014/108
Query!
Summary
Brief summary
To establish the feasibility, patient acceptability, effect on blood pressure and thereby overall potential of a simplified treatment strategy with 'hypertension polypill', which includes four common blood pressure lowering medications each at 1/4 strength dose.
This pilot study will be double blind randomised placebo- controlled crossover trial of 50 patients with established hypertension not on any medical therapy. Subjects will be randomised into two arms - intervention (Quadpill) and control (placebo)- for a period of four weeks. They will undergo office blood pressure as well as 24 hour ambulatory BP assessment at baseline and in 4th week in addition to safety monitoring blood tests. Thereafter there will be a 2 week washout phase prior to crossing over to opposite arm of the study. The patients will undergo another baseline blood and 24 hour ambulatory BP assessment. The study will conclude at 10 week with repeat measurements. The outcomes assessed will be change in the mean blood pressure, safety, tolerability and acceptability.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
45642
0
Prof Clara Chow
Query!
Address
45642
0
Westmead Applied Research Centre Faculty of Medicine and Health
The University of Sydney/Westmead Hospital
Westmead NSW 2145
Query!
Country
45642
0
Australia
Query!
Phone
45642
0
+61 2 8890 3125
Query!
Fax
45642
0
+61 2 8890 8323
Query!
Email
45642
0
[email protected]
Query!
Contact person for public queries
Name
45643
0
Dr Jay Thakkar
Query!
Address
45643
0
Level 2, Cardiology Department,
Westmead Hospital.
Cnr Darcy road - Hawkesbury road.
Westmead. NSW. 2145
Query!
Country
45643
0
Australia
Query!
Phone
45643
0
+61 2 9845 5555
Query!
Fax
45643
0
Query!
Email
45643
0
[email protected]
Query!
Contact person for scientific queries
Name
45644
0
Prof Clara Chow
Query!
Address
45644
0
Westmead Applied Research Centre Faculty of Medicine and Health
The University of Sydney/Westmead Hospital
Westmead NSW 2145
Query!
Country
45644
0
Australia
Query!
Phone
45644
0
+61 2 8890 3125
Query!
Fax
45644
0
+61 2 8890 8323
Query!
Email
45644
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Not permitted under ethics approval
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Current supporting documents:
Updated to:
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
23312
Statistical analysis plan
Results publications and other study-related documents
Documents added manually
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
Study results article
Yes
February 9, 2017
365646-(Uploaded-31-07-2019-10-20-58)-Journal results publication.pdf
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
2017
https://dx.doi.org/10.1016/S0140-6736%2817%2930260-X
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF